Andexanet Alfa

Overview

5 out of 5 (1 Reviews)

Credits

1.00

Post Assesment Questions

5

Release Date

5 Oct 2020

Expiration Date

31 Jan 2022

Last Reviewed

31 Jan 2021

Estimated Time To Finish

60 Minutes

Stay up to date on the latest medical knowledge

Start This Activity
 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Andexanet alfa is a recombinant modified Factor Xa protein approved by the FDA in May 2018 for the reversal of apixaban and rivaroxaban in patients with life-threatening or uncontrolled bleeding. Anticoagulation reversal is often a critical need when therapy does not work as planned, and bleeding ensues. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent to members of the interprofessional team to use andexanet alfa when factor Xa reversal is appropriate.

Target Audience

This activity has been designed to meet the educational needs of pharmacists.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify the mechanism of action and indication for the use of andexanet alfa.
  • Review the dosing parameters for andexanet alfa.
  • Summarize the adverse effects and indicate appropriate monitoring and toxicity of andexanet alfa.
  • Explain the importance of anticoagulation monitoring and how it affects therapeutic strategy as it pertains to improving care coordination among the interprofessional team when initiating andexanet alfa factor Xa inhibitor reversal to achieve the best outcomes.

Pharmacy Activity Type:
General Pharmacy Topic


Author(s) / Contributors Disclosure of Conflicts of Interest

Each author, editor, faculty and planning committee member have completed a disclosure form indicating that neither they nor their spouse/partner has a financial interest/arrangement or affiliation that could be perceived as a real or apparent conflict of interest related to the content of this activity.

COMMERCIAL SUPPORT: This activity has received NO commercial support.

Contributors

Hover over the contributor names to see details and disclosures of any financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Continuing Education Accreditation Information


 

 

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare. This activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare, and StatPearls Publishing, LLC.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and StatPearls Publishing, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.00 contact hours for pharmacists.

FL Board of Pharmacy Tripartite, approval #20-608156.

Cancellation Policy: Cancellations must be received in writing and a money-back guarantee is provided if not completely satisfied.

  • StatPearls and AKH reserve the right to cancel any course due to unforeseen circumstances. StatPearls and AKH will not be responsible for other expenses incurred by the participant in the unlikely event that the program is canceled.

Equal Opportunity

  • StatPearls and AKH are Equal Opportunity / Affirmative Action / Equal Access Institutions. 

Medium or Media Used:

  • Computer Requirements:  Internet Access
  • E-mail Address

Instructions for Credit

  1. Register for the activity and create a StatPearls login.     
  2. Review the required accreditation information:  Target audience, learning objectives, and disclosure information.
  3. Complete the entire self-study activity.
  4. Complete the post-test assessments.
  5. Successfully pass the post-test with a minimum score of 100%.
  6. Complete the evaluation form.

StatPearls and AKH adhere to provider standards regarding commercial support of continuing education. It is the policy of StatPearls and AKH that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that authors and editors will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made prior to starting the activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

  • If you have concerns regarding the CE system, please contact support@statpearls.com, or call 727-289-9796.
  • If you have concerns regarding CE, please contact service@akhcme.com or call AKH 877-AKH-CME4.

 

Media Usage Rights

The contributors and editors of StatPearls have attested that all associated media (images and video) have been legally cleared for use with this activity.  All copyrights are reserved.

    Reviews

    Deborah Z. on 2/26/2021

    Unlimited Pharmacist CE

    Stay up to date on the latest medical knowledge with 3335 CE activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 3743.25 hours of CE.

    Single Activity

    Take this single activity

    $19 1 activity

    6 Month Unlimited Pharmacist CE

    Access to all the Unlimited Pharmacist CE activities in all specialties.

    $59 per half year per user

    1 Year Unlimited Pharmacist CE

    Access to all the Unlimited Pharmacist CE activities in all specialties.

    $79 per 1 year per user